FINCH THERAPEUTICS GROUP, INC.
200 Inner Belt Road, Suite 400
Somerville, MA 02143
May 31, 2022
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F. Street, N.E.
Washington, D.C. 20549
Attention: Alan Campbell
Re: | Finch Therapeutics Group, Inc. |
Registration Statement on Form S-3 (File No. 333-265173)
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Finch Therapeutics Group, Inc. (the Company) hereby requests that the Securities and Exchange Commission (the Commission) accelerate the effective date of the Companys Registration Statement on Form S-3 (File No. 333-265173) (the Registration Statement), so that it will be declared effective at 4:00 p.m. Eastern Time on June 2, 2022, or as soon as possible thereafter. The Company hereby authorizes Marc Rubenstein and William Michener, counsel to the Company, to orally modify or withdraw this request for acceleration.
It would be appreciated if, as soon as the Registration Statement is declared effective, you would inform William Michener of Ropes & Gray LLP, counsel to the Company, at (617) 951-7247.
Very truly yours, | ||
FINCH THERAPEUTICS GROUP, INC. | ||
By: | /s/ Joseph Vittiglio | |
Joseph Vittiglio | ||
Chief Business and Legal Officer |